Payment overview · 2025
General Payments
$131.00
7 reported records · 4 companies
Healthcare provider profile · identity verified
Melissa Rice, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · LAFAYETTE, TN · NPI 1689151920
Verified facts
What the public records show
CMS Open Payments records show Melissa Rice, APRN received $131.00 in general payments during 2025 across 7 reported records.
Corcept Therapeutics accounted for 40.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $53.14 | 40.6% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $43.77 | 33.4% | 2 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.52 | 14.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.57 | 11.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $131.00 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $53.14 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $43.77 | 2 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $19.52 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.57 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 97 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
97 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 313 | 120 |
| Gabapentin | Gabapentin | 294 | 73 |
| Lisinopril | Lisinopril | 294 | 108 |
| Atorvastatin Calcium | Atorvastatin Calcium | 254 | 96 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 229 | 82 |
| Omeprazole | Omeprazole | 214 | 76 |
| Azithromycin | Azithromycin | 193 | 143 |
| Metformin Hcl | Metformin Hcl | 192 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 180 | 68 |
| Furosemide | Furosemide | 179 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 173 | 68 |
| Metoprolol Tartrate | Metoprolol Tartrate | 162 | 58 |
| Alprazolam | Alprazolam | 145 | 36 |
| Potassium Chloride | Potassium Chloride | 144 | 68 |
| Montelukast Sodium | Montelukast Sodium | 142 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 137 | 57 |
| Losartan Potassium | Losartan Potassium | 134 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 133 | 53 |
| Meloxicam | Meloxicam | 118 | 45 |
| Trazodone Hcl | Trazodone Hcl | 114 | 36 |
| Carvedilol | Carvedilol | 97 | 44 |
| Mounjaro | Tirzepatide | 97 | 23 |
| Buspirone Hcl | Buspirone Hcl | 95 | 33 |
| Fluconazole | Fluconazole | 93 | 56 |
| Duloxetine Hcl | Duloxetine Hcl | 87 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 40 |
| Simvastatin | Simvastatin | 87 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 86 | 37 |
| Clonazepam | Clonazepam | 83 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 82 | 25 |
| Tramadol Hcl | Tramadol Hcl | 80 | 26 |
| Mupirocin | Mupirocin | 79 | 57 |
| Doxycycline Hyclate | Doxycycline Hyclate | 77 | 64 |
| Sertraline Hcl | Sertraline Hcl | 76 | 25 |
| Cefdinir | Cefdinir | 74 | 61 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 70 | 58 |
| Famotidine | Famotidine | 69 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 69 | 24 |
| Alendronate Sodium | Alendronate Sodium | 68 | 21 |
| Allopurinol | Allopurinol | 68 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 16 |
| Azelastine Hcl | Azelastine Hcl | 65 | 26 |
| Prednisone | Prednisone | 65 | 46 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 63 | 48 |
| Glimepiride | Glimepiride | 63 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 62 | 17 |
| Januvia | Sitagliptin Phosphate | 61 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 58 | 35 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 54 | 45 |
| Eliquis | Apixaban | 54 | 16 |
| Ozempic | Semaglutide | 54 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 54 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 53 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 20 |
| Nystatin | Nystatin | 51 | 40 |
| Levofloxacin | Levofloxacin | 50 | 37 |
| Jardiance | Empagliflozin | 48 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 18 |
| Mirtazapine | Mirtazapine | 46 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 15 |
| Baclofen | Baclofen | 41 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 41 | 16 |
| Aripiprazole | Aripiprazole | 40 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | 19 |
| Dexamethasone | Dexamethasone | 38 | 37 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | 12 |
| Lorazepam | Lorazepam | 38 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | 13 |
| Synthroid | Levothyroxine Sodium | 33 | 11 |
| Bumetanide | Bumetanide | 31 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 16 |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | 14 |
| Ibuprofen | Ibuprofen | 30 | 12 |
| Meclizine Hcl | Meclizine Hcl | 30 | 14 |
| Pregabalin | Pregabalin | 30 | suppressed |
| Naproxen | Naproxen | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 22 |
| Methocarbamol | Methocarbamol | 28 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Atenolol | Atenolol | 27 | 13 |
| Dexlansoprazole Dr | Dexlansoprazole | 27 | suppressed |
| Estradiol | Estradiol | 27 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | 11 |
| Glipizide | Glipizide | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Roflumilast | Roflumilast | 25 | suppressed |
| Sucralfate | Sucralfate | 24 | 11 |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Cephalexin | Cephalexin | 23 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 23 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Ofloxacin | Ofloxacin | 22 | 20 |
| Olanzapine | Olanzapine | 22 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Metolazone | Metolazone | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 19 | 19 |
| Acyclovir | Acyclovir | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Azathioprine | Azathioprine | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $131.00 · 7 records | Corcept Therapeutics | CAPLYTA, GIVLAARI, Korlym, MOUNJARO, ZEPBOUND | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error